12:00 AM
 | 
Feb 18, 2013
 |  BC Week In Review  |  Company News  |  Deals

Cellmid, Fujikura Kasei Co. Ltd. deal

Fujikura received an option to license use of Cellmid's midkine ( MDK; MK) diagnostic antibodies on Fujikura's latex-based assay technology. Cellmid will receive an upfront fee and is eligible for an...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >